![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif)
Prostate Cancer Screening
Ian M. Thompson, MD
Arch Fam Med. 1995;4(4):307-308.
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
SCREENING FOR prostate cancer has become an integral part of the practice of almost every medical specialty that treats men over the age of 50 years in the United States. Despite its being 90 years since the first radical prostatectomy and the recommendation for screening1 and that thousands of men have been screened with both the digital rectal examination and, more recently, prostate-specific antigen (PSA), little is known regarding the important outcomes of this activity.2,3 What is known is that screening will increase the number of tumors that are detected and that the stage at detection is usually clinically organ confined.4 Although it is emotionally acceptable that early diagnosis and treatment should result in a reduction in morbidity and mortality from the disease, this remains to be demonstrated. The virtual ubiquitous nature of the disease, which is present in as many as 30% of men in their
. . . [Full Text PDF of this Article]
Author Affiliations
Brooke Army Medical Center San Antonio, Tex
|